Neuren Bull Excited by European Regulator Changing Mind on Daybue
Dow Jones
Jun 29
2342 GMT - Bell Potter raises its price target on Neuren Pharmaceuticals by 6.8% to A$23.50/share after a key European regulator reverses its initial rejection of the trofinetide treatment for Rett Syndrome. Drug advisory body CHMP has decided, after a re-examination, to adopt a positive recommendation. Analyst Thomas Wakim says it's likely that trofinetide, also known as Daybue, will be approved in Europe in around two months. "The addition of Daybue European sales adds A$2.00/share to our NPV valuation based on current forecasts," Bell Potter says. Neuren ended last week at A$12.20. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 28, 2026 19:42 ET (23:42 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.